Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

IMPORTANCE: Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an understanding of this combination’s tolerability and impact on minimal residual disease (MRD) negativity because this end point has be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Oncol
Hauptverfasser: Korde, Neha, Roschewski, Mark, Zingone, Adriana, Kwok, Mary, Manasanch, Elisabet E., Bhutani, Manisha, Tageja, Nishant, Kazandjian, Dickran, Mailankody, Sham, Wu, Peter, Morrison, Candis, Costello, Rene, Zhang, Yong, Burton, Debra, Mulquin, Marcia, Zuchlinski, Diamond, Lamping, Liz, Carpenter, Ashley, Wall, Yvonne, Carter, George, Cunningham, Schuyler C., Gounden, Verena, Sissung, Tristan M., Peer, Cody, Maric, Irina, Calvo, Katherine R., Braylan, Raul, Yuan, Constance, Stetler-Stevenson, Maryalice, Arthur, Diane C., Kong, Katherine A., Weng, Li, Faham, Malek, Lindenberg, Liza, Kurdziel, Karen, Choyke, Peter, Steinberg, Seth M., Figg, William, Landgren, Ola
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6662597/
https://ncbi.nlm.nih.gov/pubmed/26181891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2015.2010
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge